Real-world cohort studies further demonstrate that SGLT2 inhibitors are preferentially initiated in patients with chronic kidney disease or other high-risk profiles, a prescription-channeling pattern that may leave residual confounding even after propensity-score matching with a detailed diabetic retinopathy score [23,28,29]. The gene discussed is SLC5A2; the disease is chronic kidney disease.